Trial
NCT01564563
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Acquired Bleeding Disorder
Intervention
standard therapy
Why stopped
Trial enrollment was prematurely terminated due to excessively slow patient recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-27